Healio

FDA approves expanded indication of furosemide injection for NYHA class IV heart failure

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication of self-administered subcutaneous furosemide for patients with HF. The ...
Seeking Alpha

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early ...

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias NYHA heart failure ...
Renal & Urology News

FDA Approves Expanded CHF Indication for Furoscix

Credit: scPharmaceuticals. Previously, the novel furosemide delivery system was only indicated for congestion due to fluid overload in adult patients with NYHA Class II and Class III CHF. The Furoscix ...
WPRI 12

Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit

Four out of the five patients in the low-dose group have shown improvements in New York Heart Association (NYHA) heart failure classification at 6 months, with clinically meaningful improvements in ...